Research Use Only. Not for human consumption, medical use, diagnosis, or treatment. By purchasing, you agree to laboratory use guidelines.
RETAKLIK 40mg
Investigational triple agonist targeting GLP-1, GIP and glucagon receptors — 40mg and 60mg lyophilised pens at 99%+ purity for in vitro research use only.
RETAKLIK (Also known as Reta) is an investigational triple agonist targeting GLP-1, GIP and glucagon receptors — 40mg and 60mg lyophilised pens at 99%+ purity for in vitro research use only. Pre-order now for dispatch on 10th November 2026. Strictly not for human consumption or animals.
RETAKLIK 40mg Research Specifications
Also known as Reta · Investigational Triple Agonist
RETAKLIK 40mg represents advanced metabolic receptor research. It is a synthetic 39-amino-acid peptide engineered as an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. Designed exclusively for in vitro laboratory investigations into multi-pathway cellular signalling, insulin response pathways, and energy regulation.
⚠️ Research Compliance Notice
Strictly for in vitro research and laboratory use only. Strictly not for human consumption, animal testing, clinical administration, or medical diagnostics.
Laboratory Storage & Handling Guidelines
Store refrigerated at 2°C to 8°C protected from light. Keep sealed in original container until testing. Do not freeze. Dispatched in temperature-insulated cold-pack packaging with Royal Mail Tracked 24 across the UK.
Triple Tested
HPLC & MS verified for consistent potency thresholds.
Priority Post
Discreet Next Day Delivery on all research orders.
Official APEX Partner Live Verification
Each research unit features an authentic tamper-evident holographic seal with a unique scratch-to-reveal security code. Enter your code at apexpharma.io/verify to confirm instant product authenticity and view the live Certificate of Analysis for your exact batch.